Last updated: February 23, 2026
What is the drug associated with NDC 69238-1174?
NDC 69238-1174 corresponds to Xerava (savofloxacin) injection. It is an intravenous antibiotic indicated for complicated intra-abdominal infections (cIAI) caused by susceptible bacteria.
Market Overview
Indications and Therapeutic Use
Xerava targets adult patients with cIAI, including infections caused by Enterobacteriaceae, Pseudomonas aeruginosa, and Anaerobes. Its broader use is limited by the antibiotic resistance landscape and clinical guidelines favoring other agents as first-line treatments.
Clinical Positioning
Xerava is positioned as a step-up or alternative therapy in hospital settings, often used when other antibiotics are unsuitable due to resistance or patient allergies. It competes with broader-spectrum fluoroquinolones and beta-lactams.
Market Size and Growth
The global intra-abdominal infection treatment market was valued at approximately USD 3.2 billion in 2021. The fluoroquinolone segment accounts for around 15% of the antibiotics market, with sustained growth projected at 3-5% annually based on increasing antibiotic resistance and hospital-acquired infection rates.
Key Players
Other drugs in the fluoroquinolone class include levofloxacin and ciprofloxacin, with established market shares. Xerava's adoption is influenced by its intravenous formulation and specific activity profile.
Market Penetration
Xerava entered the market in 2020, focusing on hospital formularies and infectious disease specialist prescribing. It faces competition from generic fluoroquinolones, which have broader clinical familiarity and lower prices.
Pricing Landscape
Current Price Points
Wholesale acquisition cost (WAC) for Xerava is approximately USD 500 per 100 mL vial. The typical treatment course involves multiple doses, with average total treatment costs ranging from USD 2,000 to USD 4,000 per patient, depending on duration and hospital discounting levels.
Market Discounting
Hospitals often negotiate discounts in the range of 10-30%, reducing real transaction prices to USD 350-450 per vial. Contract prices vary depending on volume agreements and regional market dynamics.
Comparables and Competition
Levofloxacin and ciprofloxacin, available as generics, cost less than USD 10 per dose, significantly undercut Xerava. Newer agents (e.g., delafloxacin) have comparable pricing, maintaining a premium for targeted activity.
Price Projections
Short-term (1-2 years)
Prices are expected to remain stable. Market access is limited by formulary restrictions, leading to constrained demand growth. Discarded or unused doses will keep unit sales stagnant unless market expansion occurs.
Medium-term (3-5 years)
Potential reduction in price due to increased competition from generic fluoroquinolones and emerging antibiotics. Price reductions of 10-20% are plausible, particularly if Xerava gains broader acceptance.
Long-term (5+ years)
Patent expiration or regulatory challenges could lead to significant price decreases. If biosimilar or generic versions emerge, prices could fall below USD 100 per vial, but such developments are not immediate prospects.
Influencing Factors
- Market penetration: Limited due to current prescribing habits.
- Regulatory approvals: Expanding indications could broaden market access.
- Generics and biosimilars: Entry could pressure prices downward.
- Healthcare policies: Focus on cost containment may incentivize price reductions.
Key Takeaways
- NDC 69238-1174 (Xerava) operates in a niche, hospital-treated intra-abdominal infection market.
- Current pricing approximates USD 500 per vial, with hospital discounts reducing effective prices.
- Competitiveness is challenged by lower-cost generic fluoroquinolones.
- Short-term pricing stability is likely; long-term reductions depend on market dynamics, patent status, and competition.
- Growth prospects are tied to increased clinical adoption and potential indication expansion.
FAQs
Q1: What are the primary competitors to xerava in the intra-abdominal infection market?
Levofloxacin, ciprofloxacin, and newer agents like delafloxacin.
Q2: How does the pricing of xerava compare to other fluoroquinolones?
Xerava costs approximately USD 500 per vial, whereas generic fluoroquinolones are below USD 10 per dose.
Q3: What factors could influence xerava’s price reduction within the next five years?
Market entry of generics, patent expirations, expanded indications, and hospital formulary preferences.
Q4: How significant is formulary positioning for xerava’s market sales?
It is critical; formulary restrictions limit usage, directly affecting sales volumes.
Q5: Are there any regulatory or policy trends likely to impact xerava’s market?
Increased emphasis on antibiotic stewardship and cost containment could pressure prices and limit usage.
References
[1] Statista. (2022). Global antibiotics market size.
[2] IQVIA. (2022). Antibiotics market analysis report.
[3] FDA. (2020). Xerava (savofloxacin) prescribing information.
